HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer - Wikidata - awgldk - TriplyDB

HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer

HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer

http://www.wikidata.org/entity/Q33909892

about

In silico identification of epitopes from house cat and dog proteins as peptide immunotherapy candidates based on human leukocyte antigen binding affinity.Trial Watch: Peptide-based anticancer vaccines.Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma Current advances in T-cell-based cancer immunotherapy Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens.Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.Immune targets and neoantigens for cancer immunotherapy and precision medicine.MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells Trial Watch: Peptide vaccines in cancer therapy.Expression analysis of cancer-testis genes in prostate cancer reveals candidates for immunotherapy.

P2860

Q33754444-5FF297E0-B46E-4747-A705-7EDBDFE3DBE0 Q34483345-141E68ED-3A71-45BB-BCD7-1F7708476967 Q34786566-997F59ED-F523-45E3-8452-25E77D5412DF Q35215158-6A38D8AF-8F89-4EB6-AE75-D8EE22C89581 Q38212231-AFA4D61E-F454-4A39-899C-006EEF48CBF8 Q38248440-A3667BE1-05D4-4807-B61E-F6C3A21F7FB8 Q39057617-1F515F86-520C-4DBD-8EC1-333D19697415 Q40987678-0A8FF2FB-8A8A-4C44-8DE6-B9BFF03B3D94 Q42734544-9C928566-A4D9-4E3A-B61F-8F13F7FAC59A Q47876991-F0135719-1654-4C8D-810F-F7D81BCC047E

P2860

HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer

http://www.wikidata.org/entity/Q33909892

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

HLA-restricted NY-ESO-1 peptid ...... tion resistant prostate cancer

@ast

HLA-restricted NY-ESO-1 peptid ...... tion resistant prostate cancer

@en

type

label

HLA-restricted NY-ESO-1 peptid ...... tion resistant prostate cancer

@ast

HLA-restricted NY-ESO-1 peptid ...... tion resistant prostate cancer

@en

prefLabel

HLA-restricted NY-ESO-1 peptid ...... tion resistant prostate cancer

@ast

HLA-restricted NY-ESO-1 peptid ...... tion resistant prostate cancer

@en

P1433

Q33909892-7A1AC072-397A-4EFB-9602-BAC5C8DDE476

P1476

Q33909892-57FEFCAA-4CE7-4DEF-B7C9-3CF021EA71DA

P2093

Q33909892-01854C7A-C264-4335-A27E-1F718FB66C61

Q33909892-16E68BD7-D2EB-4380-9930-AE8F728E0553

Q33909892-256B144F-6569-455B-B950-E604633F0EEC

Q33909892-4D68F97C-D827-431C-B1C0-65EFC39EB50E

Q33909892-572F1391-5CC4-490D-8513-6C56DF95ED15

Q33909892-9A0A8A00-7250-40B7-A28F-6E1B93563DE5

Q33909892-A9E1A8C1-8B7D-47A2-9BBC-ED71A551B195

Q33909892-BBC156D6-B910-49A4-8A0B-05D1D9B3A248

Q33909892-C4F0E27E-51C1-4DEB-B315-33FE7B11D485

Q33909892-E48C6032-F2B2-40BD-A281-DF4227BE40DC

P2860

Q33909892-0CE26F97-1597-45BC-B302-A958397F78D4

Q33909892-1176B494-43A7-4943-9D77-2BB0BA88A1DB

Q33909892-11B94F89-B238-4CBD-81E6-82E309033BFB

Q33909892-21D42FFE-5DDA-4C17-B336-5438904576AF

Q33909892-232A4B91-4BB4-4D4E-9B7A-417E8829917A

Q33909892-409D91EA-33A5-471D-BD96-AB96F455F213

Q33909892-44B5112C-9ED6-4692-9865-428F1C904C1D

Q33909892-4B25F1EC-9322-4FEA-AC73-9EB7783FE759

Q33909892-54491F10-8944-4023-82D3-4048F288EBBE

Q33909892-598BF0AD-94D8-47F5-8F97-F4B7C29A6E88

P2888

Q33909892-41FEEC5A-2A9C-406E-918F-12D7B491CDFF

P304

Q33909892-32B7AC46-B6D7-40B9-B7F4-6B7866FE8304

P31

Q33909892-DE605FE1-6D46-426E-B516-A88EC89A2182

P356

Q33909892-B69D795E-C81C-4CB5-AA10-470C3C929B08

P433

Q33909892-FF1371DC-7282-463B-ACAC-61B587087500

P478

Q33909892-94D507E7-FD21-4CDB-9F94-2C85A1CD0004

P50

Q33909892-9FA88FA7-B9E3-44B3-B31F-5913F9F6928C

P577

Q33909892-8EB746E6-3A8F-433E-9785-CDB9D8A63589

P6179

Q33909892-FDAF059C-B34E-4F0B-A196-C94DB6775BBA

P698

Q33909892-05CD9B2C-F558-43A1-B5EE-484749937F4B

P921

Q33909892-0B70B4D1-8783-4161-ACB8-1874D783AFAB

P932

Q33909892-FFC9A729-66CB-4A89-9D1B-26639A610D50

P356

S10637-013-9960-9

P1433

Investigational New Drugs

P1476

HLA-restricted NY-ESO-1 peptid ...... tion resistant prostate cancer

@en

P2093

Adrian P Gee

http://www.w3.org/2001/XMLSchema#string

Dov Kadmon

http://www.w3.org/2001/XMLSchema#string

Guru Sonpavde

http://www.w3.org/2001/XMLSchema#string

Helen Y Wang

http://www.w3.org/2001/XMLSchema#string

Martha P Mims

http://www.w3.org/2001/XMLSchema#string

Michael M Ittmann

http://www.w3.org/2001/XMLSchema#string

Mingjun Wang

http://www.w3.org/2001/XMLSchema#string

Rong-Fu Wang

http://www.w3.org/2001/XMLSchema#string

Teresa G Hayes

http://www.w3.org/2001/XMLSchema#string

Teresa Joe

http://www.w3.org/2001/XMLSchema#string

P2860

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Improved endpoints for cancer immunotherapy trials

Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.

P2888

s10637-013-9960-9

P304

235-242

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-013-9960-9

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Leif E. Peterson

P577

2013-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1007843943

http://www.w3.org/2001/XMLSchema#string

P698

23609828

http://www.w3.org/2001/XMLSchema#string

P921

P932

4100683

http://www.w3.org/2001/XMLSchema#string